(Q36786086)

16 August 2017

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes (English)

1 reference

16 August 2017

0 references

1 reference

10

Hannele Yki-Järvinen

1 reference

16 August 2017

4

Richard M Bergenstal

1 reference

16 August 2017

9

Nathalie Jeandidier

1 reference

16 August 2017

Matthew C Riddle

1

1 reference

16 August 2017

Geremia B Bolli

2

1 reference

16 August 2017

Philip D Home

3

1 reference

16 August 2017

Monika Ziemen

5

1 reference

16 August 2017

Isabel Muehlen-Bartmer

6

1 reference

16 August 2017

Marek Wardecki

7

1 reference

16 August 2017

Laetitia Vinet

8

1 reference

16 August 2017

3 February 2016

1 reference

Diabetes technology & therapeutics

16 August 2017

1 reference

16 August 2017

18

1 reference

16 August 2017

4

1 reference

16 August 2017

252-257

1 reference

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4827283

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4827283

Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4827283

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4827283

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4827283

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4827283

Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4827283

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26840338

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26840338

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1089/DIA.2015.0290

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

26840338

1 reference